Eleni Lagkadinou, M.D.

Dr. Eleni Lagkadinou is the Vice President of Oncology Early Development (OED) at AbbVie. In her role, she is responsible for leading a cross-functional group focused on rapidly advancing early-stage research and development efforts, that drive innovation in oncology and support AbbVie’s mission to bring novel treatment options to patients. Integrated into AbbVie’s broader R&D organization, the OED group is committed to delivering high quality early data that help accelerate development programs and enable the initiation of registrational studies faster.

Prior to joining AbbVie, Dr. Lagkadinou served as the Executive Leader of early development oncology at Roche Pharma AG. Prior to her role at Roche, she served as VP of clinical development oncology and infectious diseases, BioNTech SE where she led clinical development and approval with Pfizer of the SARS-CoV-2 (COVID-19) vaccine. In a career spanning over 25 years, Dr. Lagkadinou has cared for cancer patients in the clinic and her research work has led to significant advancements in cancer research, including understanding of the role of Bcl-2 in acute myeloid leukemia (AML) and development of treatments that exploit the presence of DNA damage in human cancers. Dr Lagkadinou finds purpose in mentoring talents to grow in their careers and building inclusive teams fostering individual and collective growth.

Dr. Lagkadinou received her MD and PhD from the University of Patras in Greece and continued her academic work at James Wilmott Cancer Center in the University of Rochester.